#Sweden #Stockholm #Nevisense #SciBase #Rights Issue

SciBase Opens Subscription Period for Rights Issue

As of December 27, 2024, SciBase Holding AB, a notable player in the medical technology landscape, has officially commenced the subscription period for its latest rights issue. This new initiative is set to enhance the company’s growth opportunities by raising significant capital through offering units composed of newly issued shares and warrants.

Announced on November 12, 2024, this rights issue allows investors to acquire one unit, which is made up of three shares and three series TO 3 warrants. The subscription period will last until January 13, 2025. Stakeholders are encouraged to check with their banks, as certain institutions may impose earlier deadlines for subscriptions.

Financial Highlights of the Rights Issue

The financial strategy behind this rights issue is quite compelling. With a subscription price of SEK 1.35 per unit—equating to SEK 0.45 per share—SciBase anticipates an influx of approximately SEK 59.3 million prior to the deduction of issuing costs, should all units be fully subscribed. The original share price reflects values observed on Nasdaq First North Growth Market as of November 11, 2024, ensuring that investor interest remains aligned with market valuations.

Existing shareholders were granted unit rights based on their share ownership as of December 20, 2024, where every share held allowed investors to claim one unit right. For every five unit rights, shareholders can subscribe for one unit. This mechanism is designed to reward existing investors while attracting new ones to join in on this growth venture. Moreover, 38.6 percent of the rights issue is already secured through commitments from existing shareholders and management, with additional backing from external entities like Life Science Invest Fund 1 ApS and Exelity AB, which covers up to 50.4 percent of the offering.

Future Projections and Commitments

Alongside the subscription offerings, important activities are scheduled, such as the exercise of TO 3 warrants between November 24 and December 5, 2025. The exercise price for these warrants is set to be 80 percent of the average share price leading up to the measurement period, respecting minimum and maximum limits to protect investors. If fully subscribed and all warrants are exercised successfully, SciBase could potentially receive another SEK 59.3 million, amplifying their capital potential significantly.

The rights issue signifies more than just an opportunity for immediate financing; it reflects SciBase's commitment to bolstering its market position. The company specializes in early detection and prevention within the dermatology sector, focusing on innovative platforms like Nevisense, which utilizes AI for enhanced diagnostic accuracy. By investing in this venture, stakeholders are not simply funding a company; they are contributing to advancements in health technology aimed at reducing patient suffering and healthcare costs.

Conclusion

For those interested in participating in this investment opportunity, comprehensive details are available in the company's published EU growth prospectus. Investors are urged to consult the documents on SciBase's official website or reach out to financial advisors for personalized insights. The rights issue highlights both the readiness of SciBase to evolve and its dedication to improving dermatological care through cutting-edge technology. As the subscription period unfolds, market observers will be watching closely to gauge investor enthusiasm and the subsequent impact on SciBase's trajectory in the medical technology arena.